The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a Lactobacillus sp which colonizes the gastrointestinal tract. The anti-infective activity can be a bacteriocidal or bacteriostatic peptide, an antibody or fragment thereof which specifically recognizes a pathogen, or a phage, or a lytic peptide from a phage which specifically targets a certain pathogen.

The present invention relates to a composition for control of microbial development of an edible substance the composition comprises a supernatant comprising a bacteriocin produced from fermentation of a bacteriocin producing bacteria and an organic acid produced from fermentation of a bacteriocin producing bacteria, wherein organoleptic characteristics of the edible substance are not significantly altered.

Primary leachate is used as a plant growth stimulant. A fermentation medium is fermented with a microbial culture in a bioreactor to produce a primary leachate comprising microorganisms derived from the microbial culture and/or naturally occurring microorganisms. The primary leachate is isolated from the bioreactor, diluted with water, and used to irrigate plants to reduce bacterial diversity and stimulate beneficial microorganisms in the rhizosphere around the plants. The fermentation medium may be organic waste, preferably food waste. A secondary leachate may also be used as a plant growth stimulant. The primary leachate is used to culture black soldier fly larvae with a substrate in a secondary processing bioreactor under suboptimal culture conditions, thereby producing secondary leachate. Melanin is extracted therefrom by acid precipitation. The secondary leachate is then diluted with water and used to irrigate plants, reducing bacterial diversity and stimulating beneficial microorganisms in the rhizosphere around the plants.

Primary leachate is used as a plant growth stimulant. A fermentation medium is fermented with a microbial culture in a bioreactor to produce a primary leachate comprising microorganisms derived from the microbial culture and/or naturally occurring microorganisms. The primary leachate is isolated from the bioreactor, diluted with water, and used to irrigate plants to reduce bacterial diversity and stimulate beneficial microorganisms in the rhizosphere around the plants. The fermentation medium may be organic waste, preferably food waste. A secondary leachate may also be used as a plant growth stimulant. The primary leachate is used to culture black soldier fly larvae with a substrate in a secondary processing bioreactor under suboptimal culture conditions, thereby producing secondary leachate. Melanin is extracted therefrom by acid precipitation. The secondary leachate is then diluted with water and used to irrigate plants, reducing bacterial diversity and stimulating beneficial microorganisms in the rhizosphere around the plants.

The present invention relates to a protein derived from lactic acid bacteria and a method for producing the same. The lactic acid bacteria-derived protein of the present invention is a purified protein isolated from lactic acid bacteria (Lactobacillus rhamnosus) having an excellent therapeutic effect against colorectal cancer. It has been demonstrated to have a remarkable effect against colorectal diseases, and thus is expected to be widely used as a natural protein therapeutic agent against colorectal diseases in the medical field.

The present invention relates to a protein derived from lactic acid bacteria and a method for producing the same. The lactic acid bacteria-derived protein of the present invention is a purified protein isolated from lactic acid bacteria (Lactobacillus rhamnosus) having an excellent therapeutic effect against colorectal cancer. It has been demonstrated to have a remarkable effect against colorectal diseases, and thus is expected to be widely used as a natural protein therapeutic agent against colorectal diseases in the medical field.

Provided are a promoter polynucleotide, a signal polypeptide and a polynucleotide encoding the signal polypeptide, and use thereof. A vector and a host cell each including the promoter polynucleotide and the polynucleotide encoding the signal polypeptide may efficiently express and/or extracellularly secrete a foreign protein.

Provided are a promoter polynucleotide, a signal polypeptide and a polynucleotide encoding the signal polypeptide, and use thereof. A vector and a host cell each including the promoter polynucleotide and the polynucleotide encoding the signal polypeptide may efficiently express and/or extracellularly secrete a foreign protein.

The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).

The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).